During the past decade, Johns Hopkins Singapore International Medical Centre conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 14 clinical trials were completed, i.e. on average, 280% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Johns Hopkins Singapore International Medical Centre" #1 sponsor was "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins" with 7 trials, followed by "National Cancer Institute (NCI)" with 5 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Cancer Therapeutics Research Group" with 3 trials sponsored and "Puma Biotechnology, Inc." with 3 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Johns Hopkins Singapore International Medical Centre" #1 collaborator was "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Australasian Gastro-Intestinal Trials Group" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "CIMAB (Cuba)" with 1 trials as a collaborator and "ETOP IBCSG Partners Foundation" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Johns Hopkins Singapore International Medical Centre" are "Breast Cancer" (8 trials), "Hepatocellular Carcinoma" (2 trials), "Lung Cancer" (2 trials), "NSCLC" (2 trials) and "Nasopharyngeal Carcinoma" (2 trials). Many other conditions were trialed in "Johns Hopkins Singapore International Medical Centre" in a lesser frequency.

Most popular intervention types in "Johns Hopkins Singapore International Medical Centre" are "Drug" (33 trials), "Other" (6 trials), "Biological" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (4 trials), "Laboratory Biomarker Analysis" (4 trials), "Placebo" (3 trials), "Doxorubicin" (2 trials) and "Erlotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Johns Hopkins Singapore International Medical Centre" are 30 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Johns Hopkins Singapore International Medical Centre". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Johns Hopkins Singapore International Medical Centre, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Johns Hopkins Singapore International Medical Centre, 6 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Johns Hopkins Singapore International Medical Centre has several departments that took part in Clinical trials: "Puno Global Non-Communicable Disease Research Site, School of Medicine, Johns Hopkins University" - 2 trials